相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Jens G. Lohr et al.
CANCER CELL (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma
M. Affer et al.
LEUKEMIA (2014)
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolo Bolli et al.
NATURE COMMUNICATIONS (2014)
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
P. Leif Bergsagel et al.
BLOOD (2013)
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
Joseph R. Mikhael et al.
MAYO CLINIC PROCEEDINGS (2013)
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma
Brian A. Walker et al.
BLOOD (2012)
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy
Marta Chesi et al.
BLOOD (2012)
Clonal competition with alternating dominance in multiple myeloma
Jonathan J. Keats et al.
BLOOD (2012)
Molecular pathogenesis of multiple myeloma and its premalignant precursor
W. Michael Kuehl et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival
Torsten Steinbrunn et al.
BLOOD (2011)
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells
Eva Martinez-Garcia et al.
BLOOD (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival
Kevin D. Boyd et al.
CLINICAL CANCER RESEARCH (2011)
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma
W-J Chng et al.
LEUKEMIA (2011)
MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites
Huadong Pei et al.
NATURE (2011)
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman et al.
NATURE (2011)
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study
Angela Dispenzieri et al.
LANCET (2010)
A monoclonal gammopathy precedes multiple myeloma in most patients
Brendan M. Weiss et al.
BLOOD (2009)
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
R. Fonseca et al.
LEUKEMIA (2009)
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies
Marta Chesi et al.
CANCER CELL (2008)
Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma
Jonathan J. Keats et al.
CANCER CELL (2007)
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
PL Bergsagel et al.
BLOOD (2005)
分享论文
